X T L Biopharmaceuticals Ltd (XTLB)

$1.84

-0.02

(-1.08%)

Market is closed - opens 8 PM, 11 Nov 2024

Performance

  • $1.73
    $1.86
    $1.84
    downward going graph

    5.98%

    Downside

    Day's Volatility :6.99%

    Upside

    1.08%

    downward going graph
  • $0.76
    $4.99
    $1.84
    downward going graph

    58.7%

    Downside

    52 Weeks Volatility :84.77%

    Upside

    63.12%

    downward going graph

Returns

PeriodX T L Biopharmaceuticals LtdIndex (Russel 2000)
3 Months
-27.84%
0.0%
6 Months
-23.33%
0.0%
1 Year
128.17%
0.0%
3 Years
-50.8%
-27.1%

Highlights

Market Capitalization
9.9M
Book Value
$0.01
Earnings Per Share (EPS)
-0.03
PEG Ratio
0.0
Wall Street Target Price
30.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-13.78%
Return On Equity TTM
-13.07%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-764.0K
Diluted Eps TTM
-0.03
Quarterly Earnings Growth YOY
-0.76
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Analyst Forecast

What analysts predicted

Upside of 1530.43%

Current $1.84
Target $30.00

Technicals Summary

Sell

Neutral

Buy

X T L Biopharmaceuticals Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
X T L Biopharmaceuticals Ltd
X T L Biopharmaceuticals Ltd
-15.98%
-23.33%
128.17%
-50.8%
43.75%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.16%
-14.42%
3.52%
34.42%
140.62%
Biontech Se
Biontech Se
-5.81%
20.18%
11.4%
-51.12%
460.49%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.41%
83.28%
68.63%
50.84%
200.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.42%
23.33%
40.2%
170.42%
155.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
X T L Biopharmaceuticals Ltd
X T L Biopharmaceuticals Ltd
NA
NA
0.0
0.0
-0.13
-0.14
NA
0.01
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.41
20.41
1.2
44.89
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.1
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.13
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
X T L Biopharmaceuticals Ltd
X T L Biopharmaceuticals Ltd
NA
$9.9M
43.75%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
140.62%
20.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
460.49%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.1B
200.09%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.9B
155.94%
32.84
-4.51%

Insights on X T L Biopharmaceuticals Ltd

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 50.8% return, outperforming this stock by 101.6%

Institutional Holdings

  • Noked Israel Ltd

    3.65%
  • Morgan Stanley - Brokerage Accounts

    1.22%
  • Citadel Advisors Llc

    0.28%
  • Rhumbline Advisers

    0.10%

Company Information

xtl biopharmaceuticals ltd. (nasdaq:xtlb, tase:xtlb.ta) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. the company’s lead drug candidate, hcdr1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (sle). treatments currently on the market for sle are not effective enough for most patients and some have significant side effects. robust clinical data on hcdr1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.

Organization
X T L Biopharmaceuticals Ltd
Employees
0
CEO
Mr. Shlomo Spokone Shalev
Industry
Health Technology

FAQs